Nasal Protollin in Early Symptomatic Alzheimer's Disease

Summary

In this research study investigators aim to learn more about a new drug called Protollin as a possible new treatment for Alzheimer's Disease (AD). The primary goal is to assess the safety and tolerability.

Timeline

Start

2021-11-18

Primary completion

2022-09-22

Completion

2023-02-21

Publications

• Kolypetri P, da Silva P, Francisco RS Jr, Frenkel D, Cecere RR, Kiliaan PCJ, Montini F, Saxena S, Clementi WA, Liu X, Sun C, Bergmark RW, Singhal T, Saraceno TJ, Zimmermann J, Gale SA, Selkoe DJ, Chitnis T, Weiner HL. Nasal administration of Protollin enhances monocyte phagocytosis and decreases CD8+ T cell cytotoxicity in subjects with early Alzheimer's disease: a Phase 1 clinical trial. NPJ Aging. 2026 Jun 5. doi: 10.1038/s41514-026-00397-3. Online ahead of print.

Drugs

Indications